Identification of a high-risk immunogenic prostate cancer patient subset as candidates for T-cell engager immunotherapy and the introduction of a novel albumin-fused anti-CD3 × anti-PSMA bispecific design

BACKGROUND: Cancer immunotherapies such as bispecific T-cell engagers have seen limited adoption in prostate cancer (PC), possibly due to differing levels of cancer receptor expression and effector T-cell infiltration between patients and inherent defects in T-cell engager design. METHODS: CD8(+) T-...

Descripción completa

Detalles Bibliográficos
Autores principales: Glud, Eske N., Rasmussen, Martin, Zhang, Yonghui, Mandrup, Ole A., Salachan, Paul Vinu, Borre, Michael, Sørensen, Karina Dalsgaard, Howard, Kenneth A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727128/
https://www.ncbi.nlm.nih.gov/pubmed/36243890
http://dx.doi.org/10.1038/s41416-022-01994-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727128/
https://www.ncbi.nlm.nih.gov/pubmed/36243890
http://dx.doi.org/10.1038/s41416-022-01994-1

Ejemplares similares